-
Jain Soto posted an update 6 months, 3 weeks ago
Activity of all, except JAK2, Lyn and STAT5b, counteract GHR signaling. Loss of their function increases the GH-induced signaling in favor of aging and certain chronic diseases, exemplified by increased lung cancer risk in case of a mutation in the SOCS2-GHR interaction site. Insight in their roles in GHR signaling can be applied for cancer and other therapeutic strategies.Multiple endocrine neoplasia type 1 (MEN1) is a rare autosomal dominant inherited tumor syndrome, associated with parathyroid, pituitary, and gastro-entero-pancreatic (GEP) neuroendocrine tumors (NETs). MEN1 is usually consequent to different germline and somatic mutations of the MEN1 tumor suppressor gene, although phenocopies have also been reported. This review analyzed main biomedical databases searching for reports on MEN1 gene mutations and focused on aggressive and aberrant clinical manifestations to investigate the potential genotype-phenotype correlation. Despite efforts made by several groups, this link remains elusive to date and evidence that aggressive or aberrant clinical phenotypes may be related to specific mutations has been provided by case reports and small groups of MEN1 patients or families. In such context, a higher risk of aggressive tumor phenotypes has been described in relation to frameshift and non-sense mutations, and predominantly associated with aggressive GEP NETs, particularly pancreatic NETs. In our experience a novel heterozygous missense mutation at c.836C>A in exon 6 was noticed in a MEN1 patient operated for macro-prolactinoma, who progressively developed recurrent parathyroid adenomas, expanding gastrinomas and, long after the first MEN1 manifestation, a neuroendocrine uterine carcinoma. In conclusion, proof of genotype-phenotype correlation is limited but current evidence hints at the need for long-term interdisciplinary surveillance in patients with aggressive phenotypes and genetically confirmed MEN1.
Renal function is profoundly influenced by thyroid hormone levels. This study was designed to evaluate the association between preoperative thyroid hormones and postoperative acute kidney injury (AKI) in acute type A aortic dissection (ATAAD) patients.
A total of 88 patients with ATAAD who underwent surgeries in Beijing Anzhen Hospital and 274 healthy controls from July 2016 to December 2016 were included in this study. Propensity-score matching was used to compare thyroid hormone levels. click here Additionally, in a cohort study of ATAAD patients, multivariable regression and stratification analyses were conducted to examine the association of preoperative thyroid hormones with postoperative AKI.
Compared with healthy controls, ATAAD patients presented with lower preoperative levels of total triiodothyronine (TT3) (P < 0.01), free triiodothyronine (FT3) (P < 0.01), and thyroid-stimulating hormone (TSH) (P < 0.01) and a higher preoperative level of free thyroxine (FT4) (P < 0.01). The overall occurrence of postoperative AKI was 45.5%. Multivariate regression revealed that low levels of TT3 (OR = 0.07, 95% CI, 0.01-0.86, P = 0.04) were independently associated with postoperative AKI. Subgroup analyses showed that the association between TT3 and AKI was significant in patients with normal TSH levels (OR = 0.001 95% CI, 0.001-0.16, P < 0.01) but not in patients with lower TSH levels (P = 0.12).
The present study showed that a low level of TT3 was a predictor of postoperative AKI in ATAAD patients, especially in patients with normal TSH. The thyroid function should be checked before surgical intervention of patients with ATAAD, and patients with low T3 might be at higher risk of postoperative AKI.
The present study showed that a low level of TT3 was a predictor of postoperative AKI in ATAAD patients, especially in patients with normal TSH. The thyroid function should be checked before surgical intervention of patients with ATAAD, and patients with low T3 might be at higher risk of postoperative AKI.Weight gain and obesity are global health concerns contributing to morbidity with increased risks of cardiovascular disease, diabetes, liver steatohepatitis and cancer. Pharmacological therapies or bariatric surgery are often required for those who fail to adhere to diet and lifestyle modifications. Metformin, a widely used antidiabetic agent, seems to have a health benefit beyond its anti-hyperglycemic properties, with few side effects. Emerging evidence shows weight loss to be associated with metformin in both diabetic and non-diabetic individuals. Recently, the growth differentiation factor 15 (GDF-15), a member of the transforming growth factor beta superfamily, has been identified as a key mediator of metformin-induced weight loss. Metformin increases the secretion of GDF-15, which binds exclusively to glial cell-derived neurotrophic factor family receptor alpha-like (GFRAL). This gut-brain cytokine works as a prominent player in reducing food intake and body weight in health and disease, like anorexia nervosa and cancer. Herein, we critically review advances in the understanding of the weight-reducing effects of metformin via the GDF-15 pathway.Aggressive pituitary tumors (APTs) are associated with significant morbidity and mortality, and effective treatment options are limited. Immune checkpoint inhibitors (ICIs) have revolutionized clinical cancer care; however, there is little experience with these agents in the management of APTs. Vascular endothelial growth factor (VEGF) targeted therapy has reported success in a small number of APT case reports. Here we describe a case of pituitary carcinoma responding to ICI therapy and subsequently VEGF inhibition. We discuss the possible mechanisms and experience with ICI therapy and VEGF inhibitors in the management of APTs, biomarkers that may predict response, and the potential role of combination therapies including ICIs and temozolomide.Background The gut microbiota is recognized as a major modulator of metabolic disorders such as type 2 diabetes. Dapagliflozin, sodium glucose cotransporter 2 inhibitors (SGLT2i), enhances renal glucose excretion, and lowers blood glucose levels. The study aimed to determine the effects of dapagliflozin on fecal microbiota in a type 2 diabetic rat model. Methods Four-week-old male Sprague Dawley rats (n = 24) were fed a high-fat diet (HFD) for 8 weeks and then given a single dose of STZ injection (30 mg/kg, i.p). They were randomly divided into three groups (n = 8). Each group received intragastric infusion of normal saline (2 ml, 0.9%) or metformin (215.15 mg/kg/day) or dapagliflozin (1 mg/kg/day) for 4 weeks. Blood glucose levels and plasma insulin levels were detected during intragastric glucose tolerance. Fecal samples were collected to access microbiome by 16S ribosomal RNA gene sequencing. Results Dapagliflozin significantly decreased fasting and postprandial blood glucose levels as metformin in type 2 diabetic rats (P less then 0.